Enanta Pharmaceuticals Ownership
| ENTA Stock | USD 12.91 0.37 2.95% |
Shares in Circulation | First Issued 2011-09-30 | Previous Quarter 21.1 M | Current Value 21.2 M | Avarage Shares Outstanding 17.9 M | Quarterly Volatility 5.5 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Enanta |
Enanta Stock Ownership Analysis
About 94.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 1.81. Some equities with similar Price to Book (P/B) outperform the market in the long run. Enanta Pharmaceuticals has Price/Earnings (P/E) ratio of 366.13. The entity recorded a loss per share of 6.25. The firm had not issued any dividends in recent years. Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Enanta Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Watertown, Massachusetts. Enanta Pharmaceutica operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 155 people. To learn more about Enanta Pharmaceuticals call Jay Luly at 617 607 0800 or check out https://www.enanta.com.Besides selling stocks to institutional investors, Enanta Pharmaceuticals also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Enanta Pharmaceuticals' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Enanta Pharmaceuticals' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Enanta Pharmaceuticals Quarterly Liabilities And Stockholders Equity |
|
Enanta Pharmaceuticals Insider Trades History
About 6.0% of Enanta Pharmaceuticals are currently held by insiders. Unlike Enanta Pharmaceuticals' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Enanta Pharmaceuticals' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Enanta Pharmaceuticals' insider trades
Enanta Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Enanta Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Enanta Pharmaceuticals backward and forwards among themselves. Enanta Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Enanta Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Assenagon Asset Management Sa | 2024-03-31 | 583.7 K | D. E. Shaw & Co Lp | 2024-03-31 | 570.2 K | Renaissance Technologies Corp | 2023-12-31 | 558.5 K | Bank Of America Corp | 2024-03-31 | 516.4 K | Geode Capital Management, Llc | 2024-03-31 | 442.1 K | State Street Corporation | 2024-03-31 | 424 K | Tang Capital Management Llc | 2024-03-31 | 300 K | Two Sigma Advisers, Llc | 2024-03-31 | 282 K | Two Sigma Investments Llc | 2024-03-31 | 257.3 K | Farallon Capital Management, L.l.c. | 2024-03-31 | 2.1 M | Morgan Stanley - Brokerage Accounts | 2024-03-31 | 2 M |
Enanta Pharmaceuticals Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Enanta Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Enanta Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Enanta Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Enanta Pharmaceuticals Corporate Filings
10Q | 8th of May 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
8K | 6th of May 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F3 | 1st of May 2024 The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock | ViewVerify |
F4 | 8th of March 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| SGC | Superior Uniform Group | |
| VLN | Valens | |
| GNFT | Genfit |
Additional Information and Resources on Investing in Enanta Stock
When determining whether Enanta Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Enanta Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Enanta Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Enanta Pharmaceuticals Stock:Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Enanta Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For information on how to trade Enanta Stock refer to our How to Trade Enanta Stock guide.You can also try the Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Enanta Pharmaceuticals. If investors know Enanta will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Enanta Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.66) | Earnings Share (6.25) | Revenue Per Share 3.455 | Quarterly Revenue Growth (0.04) | Return On Assets (0.23) |
The market value of Enanta Pharmaceuticals is measured differently than its book value, which is the value of Enanta that is recorded on the company's balance sheet. Investors also form their own opinion of Enanta Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Enanta Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Enanta Pharmaceuticals' market value can be influenced by many factors that don't directly affect Enanta Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Enanta Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Enanta Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Enanta Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.